Two companies, two countries.

AstraZeneca’s name is simply the two names of the companies that formed it. The Swedish half, Astra AB, dates from 1913, when, according to Wikipedia, it was formed by a group of doctors and apothecaries in Södertälje, south-west of Stockholm. Through the twentieth century it grew into a major Swedish pharmaceutical company.

The British half was much younger. Zeneca was created in 1993, Wikipedia says, when the chemicals group Imperial Chemical Industries, better known as ICI, separated its pharmaceutical operations into a company of their own. The name Zeneca was new, coined for that separation, and it lasted as a stand-alone corporate name from 1993 until the merger of 1999.

The two companies announced their plan to combine at the end of 1998. Pharmaceutical Executive reported in its issue of 1 February 1999 that, just weeks before 1998 ended, London-based Zeneca Group and Sweden’s Astra AB had said they planned to merge, and quoted their formal statement that they were in advanced discussions about a combination “in a merger of equals transaction”. The magazine noted that Astra had recently brought its American operations, Astra USA and AstraMerck, under one umbrella, after previously sharing ownership of AstraMerck with Merck & Co. It also set the deal beside a similar merger plan announced around the same time by Hoechst of Germany and Rhône-Poulenc of France.

The deal closed quickly. The Pharma Letter reported on 7 April 1999 that the merger had been completed, after shareholders at Astra’s annual general meeting on 6 April approved it, satisfying the remaining conditions. The new company would have its headquarters in London, the publication said, and its chief executive was Tom McKillop, who said the energy and cooperation behind the speedy completion would now go into building the combined business.

A and Z, joined.

The merged company needed a mark of its own, and it arrived within weeks. Pharmaceutical Online reported on 16 June 1999 that Astra AB and Zeneca Group PLC had merged on 6 April 1999, creating AstraZeneca PLC, based in London, and that the new company had held its official opening day of operations a little over two months later.

The same report described the new logo. It said AstraZeneca had revealed a logo that was a stylized joining of the letters “A” and “Z”, placed at the end of the corporate name. The logo, it said, would appear in national advertisements in publications including The Wall Street Journal, The New York Times and The Washington Post, and on the company’s new website in the United States.

The idea is a simple piece of naming logic. The company’s name joins two older names, Astra and Zeneca, and the symbol joins two letters, the initials of those names, which also open and close the Latin alphabet. The wordmark carries the full compound name, written as a single word with a capital Z in the middle, so the join between the two predecessors stays visible in the spelling itself.

The compound name also keeps a balance between the two countries, Sweden and the United Kingdom, and between two corporate histories of very different lengths. Astra leads the name, and the Swedish company’s 1913 roots supplied the older history; Zeneca, the British half, supplied the London headquarters announced in 1999. Wikipedia describes the result as a Swedish–British company, and the company has kept that compound name, with its joined letters, ever since the merger.

Corporate marks in pharma.

Pharmaceutical corporate identities are shaped as much by corporate history as by design. Many of the names in this sector were built through mergers, and the result is often a compound of two older names, a contraction of a longer one, or a set of initials that eventually replaces the full name altogether. A rename after a merger or a spin-off is usually the moment when a new logo, a new colour and a new typeface arrive together, presented as a single programme rather than a piecemeal refresh.

The marks themselves tend towards the abstract: interlocking shapes, simple geometric symbols or a plain wordmark, rather than pictures of anything specific. Palettes are often restrained, built around one signature colour with white space and a neutral supporting set, so that the same identity can sit on a corporate report, a laboratory building and a recruitment page without changing tone.

Promotion in this field is also regulated in many countries, with rules on what companies may say about medicines and to whom. That framework pushes corporate branding towards the company name, its values and its people, while product communication follows separate rules. The guides in this round look only at the corporate side: names, marks, colours and the dated changes behind them.

From London to Cambridge.

The headquarters announced in 1999 was in London. Today AstraZeneca is based in Cambridge, England. Its global headquarters, known as the Discovery Centre, stands on the Cambridge Biomedical Campus beside Addenbrooke’s Hospital, and, according to Wikipedia, was designed by the Swiss architects Herzog & de Meuron and officially opened by Prince Charles on 23 November 2021. The same Basel practice designed the Roche Tower in Basel, which opened in 2015.

The company has also had to decide which acquired names to keep. In February 2019, PMLive reported that AstraZeneca was folding its biologics unit MedImmune, based in Gaithersburg, Maryland, into a new research structure. The company said in a statement quoted by PMLive that the MedImmune name and logo would no longer be used, while describing the legacy and culture it said the unit had stood for over its history. Wikipedia lists Alexion Pharmaceuticals among the subsidiaries that continue under their own names.

That leaves a simple brand structure at the top. The corporate name is the merged name, the symbol is the joined pair of initials, and the history is split across two countries: Södertälje and the Swedish research tradition on one side, ICI and the British chemicals industry on the other. Wikipedia notes that the company’s research is concentrated in Cambridge, in Gothenburg in Sweden and in Gaithersburg in the United States.

For a brand born from a merger, that balance matters. The headquarters moved from London to Cambridge, the subsidiaries changed and MedImmune’s name was retired, but the compound name chosen in 1999 has stayed in place. Neither predecessor’s name disappeared; both were kept, in order, in a single word, and the logo turned the two initials into one shape.

For a design guide, AstraZeneca shows how a merger can keep both founding names and turn their initials into a single symbol. Compare GSK, another British company formed by mergers, and Novartis, a 1990s merger that chose a new name instead. For this guide we use mulberry, gold and a warm cream with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep AstraZeneca’s identity on hand — save it to a board in the Made Good inspiration library.